Resmetirom

Thyroid Hormone Receptor beta Agonist — ALIMENTARY TRACT AND METABOLISM

Key facts

Resmetirom is an onp drug in the Thyroid Hormone Receptor beta Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2024. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 2C8 Inhibitors and Organic Anion Transporting Polypeptide 1B1 Inhibitors. DrugCentral lists 2 molecular targets, including THRB and THRA. Recorded indications include Nonalcoholic steatohepatitis with liver fibrosis.

• Approval status: onp (first approved 2024 by the FDA).
• Drug class: Thyroid Hormone Receptor beta Agonist.
• Mechanism of action: Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 2C8 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors.
• Molecular targets: THRB and THRA (2 listed in DrugCentral).
• Indications: Nonalcoholic steatohepatitis with liver fibrosis.
• ATC code: A05BA11 (Liver therapy).
• Molecular formula: C17H12Cl2N6O4; molecular weight 435.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Nonalcoholic steatohepatitis with liver fibrosis

Mechanism & targets

• Mechanism of action (MoA): Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 2C8 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; Thyroid Hormone Receptor beta Agonists
• Established pharmacologic class: Thyroid Hormone Receptor beta Agonist

Molecular targets (2)

Target	Gene	Action	Activity
Thyroid hormone receptor beta	THRB	partial agonist	EC50 6.68
Thyroid hormone receptor alpha	THRA	partial agonist	EC50 5.43

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2025-08-18	EMA	—	Madrigal Pharmaceuticals EU Limited
2024-03-14	FDA	—	Madrigal Pharmaceuticals Inc.

ATC classification

ATC code	Therapeutic hierarchy
A05BA11	ALIMENTARY TRACT AND METABOLISM › BILE AND LIVER THERAPY › LIVER THERAPY, LIPOTROPICS › Liver therapy

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: ABCG2
• FDA label: ABCG2 · No Clinical PGx
• HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Alanine aminotransferase increased	277.4
Aspartate aminotransferase increased	273.2
Pruritus	229.9
Blood bilirubin increased	114.1
Diarrhoea	108.0
Nausea	106.3
Blood alkaline phosphatase increased	67.7
Hepatic fibrosis marker increased	66.8
Hepatic cirrhosis	49.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Resmetirom is on its molecule page.

• Molecular formula: C₁₇H₁₂Cl₂N₆O₄
• Molecular weight: 435.23 g/mol
• CAS number: —
• InChIKey: FDBYIYFVSAHJLY-UHFFFAOYSA-N
• PubChem CID: 15981237

CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Resmetirom used for?

DrugCentral lists the following indications for Resmetirom: Nonalcoholic steatohepatitis with liver fibrosis.

How does Resmetirom work?

Resmetirom is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 2C8 Inhibitors and Organic Anion Transporting Polypeptide 1B1 Inhibitors; its molecular targets in DrugCentral include THRB (partial agonist) and THRA (partial agonist).

When was Resmetirom first approved?

Resmetirom was first approved by the FDA in 2024.

What drug class does Resmetirom belong to?

Resmetirom is in the Thyroid Hormone Receptor beta Agonist class.

What is the chemical formula of Resmetirom?

Resmetirom has the molecular formula C17H12Cl2N6O4 and a molecular weight of 435.23 g/mol.

Sources

• DrugCentral drug card 5811 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3261331 — compound record and bioactivity
• PubChem CID 15981237 — chemical identifiers
• DrugBank DB12914 — drug record
• FDA UNII RE0V0T1ES0 — substance identity
• DailyMed: FDA labels for Resmetirom — current prescribing information (label search)
• UniProt P10828 (THRB) — target protein
• UniProt P10827 (THRA) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.